This site is intended for healthcare professionals
UCB EHSF 2024
Advances in hidradenitis suppurativa
Declaration of sponsorship UCB Biopharma SRL

Transcript: Comorbidities and patient-provider viewpoints

Declaration of sponsorship UCB Biopharma SRL
Last updated:27th Feb 2024
Published:27th Feb 2024

Dr Philippe Guillem

Interview recorded Feb 2024, EHSF 2024. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.

The comorbidities session was really interesting, because it highlighted the fact that HS is really a systemic disease associated with several comorbidities. We had, for example, communication that suggested dulling the disease has an important comorbidity and it's a follicular comorbidity that could also influence the prognosis of HS. This study was from Spain. We also had studies from Spain, from Ireland, from US highlighting the well-known inflammatory comorbidities such as IBDs. And the question raised by the study is whether we can use systematic screening for IBD in HS patients for example, using calprotectin. It's probably what we are going to. Another important inflammatory comorbidity reported by US team was about non-infectious varieties that extends the field of inflammatory comorbidities.

Another very important point in HS patients in the fact that many comorbidities are on the field of cardiovascular disease and metabolic disease. We have a study from US about the association to the NASH liver fibrosis. We also had communication about the increased risk of major cardiovascular event. And it's really something important in the clinical practice to detect and screen for this cardiovascular comorbidities in HS. The interactive session was dedicated to have in the main room, the preliminary session both patients and healthcare providers. And we asked the audience to answer live to several question related to HS clinical case. And we expected, and it is what we observed different answers depending on the quality of those who answered, whether they're patients or HCPs. And the aim of the study was to demonstrate to practitioners that their answer were sometimes not received as pertinent, relevant for the patients. And we also achieve to show to the patients how the physicians are thinking when they ask some question that seem inappropriate. The main aim of this interactive session was to show patients and the physicians that they have different points of view, but they belongs to the same therapeutic team. So that was really important for this interactive session.

View the video

Welcome: